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A B S T R A C T
Background
More than three million persons are disabled by leprosy worldwide. The main complication of sensory nerve damage is neuropathic
ulceration, particularly of the feet. In this review we explored interventions that can prevent and treat secondary damage to skin and
limbs.
Objectives
To assess the effects of self-care, dressings and footwear in preventing and healing secondary damage to the skin in persons affected by
leprosy.
Search methods
We searched the Cochrane Skin Group Specialised Register (April 2008), the Cochrane Central Register of Controlled Trials (The
Cochrane Library Issue 1, 2008), MEDLINE (from 2003 to April 2008), EMBASE (from 2005 to April 2008), CINAHL (1982-2006)
and LILACS (1982- April 2008 ) as well as online registers of ongoing trials (April 2008).
Selection criteria
Randomised controlled trials involving anyone with leprosy and damage to peripheral nerves treated with any measures designed to
prevent damage with the aim of healing existing ulcers and preventing development of new ulcers.
Data collection and analysis
Two authors assessed trial quality and extracted data.
Main results
Eight trials with a total of 557 participants were included. The quality of the trials was generally poor. The interventions and outcome
measures were diverse. Although three studies that compared zinc tape to more traditional dressings found some benefit, none of these
showed a statistically significant effect. One trial indicated that topical ketanserin had a better effect on wound healing than clioquinol
cream or zinc paste, RR was 6.00 (95% CI 1.45 to 24.75). We did not combine the results of the two studies that compared topical
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phenytoin to saline dressing, but both studies found statistically significant effects in favour of phenytoin for healing of ulcer (SMD
-2.34; 95% CI -3.30 to -1.39; and SMD -0.79; 95% CI -1.20 to 0.39). Canvas shoes were not much better than PVC-boots, and
double rocker shoes did not promote healing much more than below-knee plasters.
Authors’ conclusions
One study suggested that topical ketanserin is more effective than clioquinol cream or zinc paste. Topical phenytoin (two studies) may
be more effective than saline dressing regarding ulcer healing. For the other dressings the results were equivocal. Canvas shoes were
a little better than PVC-boots, but not significantly, and the effect of double rocker shoes compared to below-knee plasters was no
different in promoting the healing of ulcers. No side effects were documented.
There is a lack of high quality research in the field of ulcer prevention and treatment in leprosy. New trials should follow the current
standards for design and reporting of randomised controlled trials.
P L A I N L A N G U A G E S U M M A R Y
Interventions for skin changes caused by nerve damage in leprosy
Three million persons are affected by nerve damage caused by leprosy (Hansen’s disease) worldwide. Leprosy is a chronic infectious
disease caused by the bacterium Mycobacterium leprae. About 30% of people with leprosy develop nerve damage that can lead to loss
of normal sensation and skin damage. The skin can crack and become infected and ulcerated. Impairment of the affected limb, caused
by nerve damage, can result in severe joint deformity and injuries. The major areas affected by sensory loss are the hands (especially
the palms), feet (especially the soles) and eyes. The drug therapy offered to those with leprosy is efficacious and has low relapse rates.
However, even with treatment, many with leprosy will go on to develop secondary damage to skin and limbs as the nerve damage
sustained cannot be reversed. In some, treatment leads to inflammatory reactions in the nerves, sometimes resulting in further damage.
Many interventions may help the healing of such ulcers. The rationale behind the use of, for example, appropriate footwear is to protect
feet from damage that can lead to superficial sores on the soles of the feet, and later ulcers and secondary infections. Self-care includes
daily management to reduce the effects of nerve function impairment. Education, information and empowerment of those affected
by leprosy (and their carers) is part of some leprosy programmes and might prevent ulcers developing. Dressings might enhance the
healing of ulcers.
We included eight trials with a total of 557 participants. Based on weak evidence we suggest that dressings with topical ketanserin may
be more effective than clioquinol cream or zinc paste and topical phenytoin may be more effective than saline dressings regarding ulcer
healing. Canvas shoes seem to be a little better than PVC-boots, but not significantly. Double rocker shoes do not show statistically
significant benefit compared to below-knee plaster in promoting healing of ulcers. Whether the interventions reduce social stigma and
lead to better quality of life were not investigated in any of the eight trials in this review. No side effects were documented.
There is a lack of high quality research in the field of ulcer prevention and treatment in leprosy. New trials should follow the current
standards for design and reporting of randomised controlled trials.
B A C K G R O U N D
Description of the condition
More than three million individuals are currently disabled by lep-
rosy (Hansen’s disease) worldwide (WHO 2006). Despite inten-
sive efforts to control the disease, the total incidence is reported
to be about 700,000 new cases per year (738,00 and 634,376 new
cases detected in 1999 and 2000 respectively), in affected countries
(Lockwood 2002b;WHO2002b). The proportion of new cases of
leprosy in children under 15 years of age was 18% in 2000 (WHO
2002). Hence person-to-person transmission remains a problem;
there are significant numbers of childhood cases and many people
suffer from the consequences of leprosy (McDougall 2002). At
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the beginning of 2003 the number of people currently on drug
treatment for leprosy was around 524,000 (WHO 2003). There
were 407,791 new cases diagnosed and reported toWHO in 2004
(WHO 2006b). Although the incidence rate is declining slowly
worldwide it is rising in a few places ( WHO 2006).
South East Asia has the highest prevalence of leprosy followed by
the Americas, Africa, the Western Pacific, Eastern Mediterranean
and Europe (WHO 2002). The seven most affected countries are
India, Brazil, theDemocraticRepublic ofCongo,Tanzania,Nepal,
Madagascar and Mozambique. Of all those identified as having
the disease, 64% live in India .
Causes
Leprosy is a chronic infectious disease caused by the bacterium
Mycobacterium leprae.
Clinical manifestations and complications
The principal manifestations are skin lesions (flat or raised patches
on the skin, sometimes a few and sometimes numerous, depend-
ing on host immunity). In those with a large number of bacteria
the skin may become diffusely thickened. Thickened or cracked
skin, or skin ulcers, may be later complications and peripheral
neuropathy, (inflammation of nerves in the limbs, which become
thickened and damaged) is common. Complications result from
nerve damage, through immune reactions and also through di-
rect invasion by the M. leprae bacteria. When the small sensory
and autonomic nerve fibres in the skin are damaged this initially
causes local loss of sensation and loss of the skin’s ability to sweat.
Damage to peripheral nerves eventually leads to more widespread
loss of sensation, skin dryness and reduced function of the mus-
cles supplied by the affected nerve. The dry skin can crack and
become infected and ulcerated, and misuse of the affected limb
can ultimately result in severe joint deformity and injuries.
The major areas affected by nerve damage in leprosy are the hands
(especially the palms), feet (especially the soles) and eyes. Themain
complication of sensory nerve damage is ulceration secondary to
sensory loss, particularly of the feet. The drug therapy offered to
people infected with M. leprae is efficacious if given for sufficient
length of time (WHO2006).However, evenwith treatment,many
persons with leprosy will go on to develop secondary damage to
skin and limbs as the nerve damage sustained cannot be reversed.
Diagnosis
Leprosy is diagnosed clinically by two principal signs:
• anaesthetic skin lesions i.e. parts of the skin that are numb
and not able to detect painful stimuli such as a pin prick;
• thickened peripheral nerves that can easily be felt through
the skin;
and by:
• positive smear i.e. evidence of the causative bacterium, M.
leprae, using microscopic examination of a sample of tissue (skin
smear).
Classification
There are two main forms of classification (Lockwood 2002a).
They are the Ridley-Jopling scheme and the World Health Orga-
nization (WHO) PB/MB (paucibacillary/multi bacillary) classifi-
cation .
Ridley-Jopling scheme
This classifies leprosy on a scale from ’tuberculoid’ to ’leproma-
tous’ based on the clinical appearance and bacterial index of le-
sions (Lockwood 2002a). ’Tuberculoid’ indicates that the body’s
immunity is good and there are few skin lesions. ’Lepromatous’
means that the body has a poor immune response to the mycobac-
teria and there is uncontrolled bacterial multiplication, many skin
lesions and also lesions in the mucosa of the nose and mouth. Pe-
ripheral nerve damage can occur at any point on the scale. Between
the extremes of ’ tuberculoid’ and ’lepromatous’ are the ’unstable
borderline tuberculoid’ and ’borderline lepromatous’ forms.
WHO classification
This classification is based on the number of skin lesions:
1. paucibacillary (PB) - up to five lesions
2. multi bacillary (MB) - greater than five lesions (and/or positive
smear at any site).
This is a simple classification scheme thatmakes treatment simpler
for field workers, but it is less specific than the Ridley-Jopling
scheme. The WHO classification system is the most widely used.
Description of the intervention
Chemotherapy with a combination of drugs (multidrug treatment
(MDT)), is used to treat leprosy. The drugs used are rifampicin,
dapsone and clofazimine - they are effective in killing bacilli, but do
not prevent further nerve damage. Virtually all people affected by
leprosy, and registered with their local health services, are treated
with MDT. Other interventions in leprosy care are aimed at pre-
vention and treatment of secondary damage to skin and limbs.
How the intervention might work
The rationale behind the use of, for example, appropriate footwear
is to protect feet from damage that can lead to superficial sores
on the soles of the feet, and later ulcers and secondary infections
(McDougall 2002). Many interventions may help the healing of
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such ulcers (Srinivasan 1989). Self-care includes daily manage-
ment to reduce the effects of nerve function impairment. Educa-
tion, information and empowerment of those affected by leprosy
(and their carers) is part of some leprosy programmes (McDougall
2002). Ketanserin is thought to decrease peripheral vascular re-
sistance. This vasodilation might have beneficial effects on cap-
illary haemodynamics and cause increase in the blood flow and
enhance healing of ulcers (Salazar 2001). Phenytoin is another
topical dressing thought to enhance healing. The rationale behind
this is that it accelerates the formation and maturation of collagen
fibres, stimulates fibroblast proliferation, and inhibits collagenase
activity (Bansal 1993).
Impact
Nerve damage can happen before, during and after chemotherapy
treatment. It affects approximately 30% of people diagnosed with
leprosy (2.6% with PB, 37% with MB, 2 years after detection
and MDT treatment) (Lockwood 2001). Approximately 6% to
9% of people with newly diagnosed leprosy present with grade 2
disabilities (visible deformity or damage present) and as many as
20% to 56% of people have established nerve damage at diagnosis
(Lockwood 2002b). These figures vary from country to country
and between disease types.
Why it is important to do this review
The key to effective management of leprosy is early diagnosis and
treatment, and early recognition and management of nerve dam-
age, combined with effective health education to prevent limb
damage. A successful treatment of the nerve damage itself can be
effective for preventing ulcer development. Corticosteroids have
been used for this purpose. However, a systematic review of three
randomised controlled trials comparingprednisolonewith placebo
or comparing different doses of corticosteroids did not show a sig-
nificant long-term effect (Van Veen 2007). Also, corticosteroids
are not well tolerated by everybody and may cause harmful effects.
It is, therefore, still of importance to find the best way of preven-
tion or treatment of skin damage.
People with leprosy are, after a few days on chemotherapy, no
longer infectious and can lead a normal social life. This has con-
tributed in recent years to themanagement of leprosy programmes
worldwide moving away from clinics dedicated to the treatment of
leprosy to primary health care services in general.However, despite
the opportunity to lead a normal social life, long-term nerve and
muscle damage can lead to great psychosocial and financial diffi-
culties, social stigmatisation and decreased quality of life. Care and
awareness of limb use will in all circumstances be necessary and
education of those with leprosy is considered a central element to
achieve a satisfactory level of self-care (Lockwood 2002c). In this
review we want to explore the effect of several types of potential
interventions that can prevent and treat secondary damage to skin
and limbs, such as education, information, self-care programmes,
dressings (i.e. zinc tape, saline, iodine, gauze soaked in different
ointments, dry dressings), skin care, footwear or other measures
designed to prevent damage.
O B J E C T I V E S
To find out if any interventions can prevent secondary damage to
the skin in people with leprosy, for example:
• self-care;
• dressings;
• appropriate footwear.
Which of the interventions are the most effective?
Do these interventions reduce social stigma and lead to better
quality of life?
Are any interventions harmful?
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Anyone with leprosy and damage to peripheral nerves who are on
multi-drug treatment or are post treatment.
Types of interventions
Education, information, self-care programmes, dressings (i.e. zinc
tape, saline, iodine, gauze soaked in different ointments, dry dress-
ings), skin care, footwear or other measures designed to prevent
damage.
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Types of outcome measures
Participants with no skin/limb damage at trial entry
Primary outcomes
(a) Prevention of skin ulcers, measured at six months and at one
year
(b) Prevention of limb deformity, measured at six months and at
one year
Secondary outcomes
(a) Prevention of cracked, thick skin
(b) Quality of life measures or other psychological or functional
measures, acceptability of intervention
(c) Cost of intervention (i.e. footwear, dressings, self-care pro-
gramme)
(d) Adverse events, either those sufficiently serious to stop inter-
vention, or minor ones reported by the participant
All of these secondary outcomes to be measured at six months and
one year.
Tertiary outcomes
(a) Quality of life measures or other psychosocial or functional
measures, acceptability of intervention
(b) Days off work, school, or other tasks
(c) Cost of interventions
(d) Adverse events, either those sufficiently serious to stop inter-
vention, or minor ones reported by the participant
Participants with existing skin ulceration at trial entry
Primary outcome
Healing of existing ulcer (measured as percentage healed at six
weeks, six months and at one year)
Secondary outcomes
(a) Prevention of recurrence of the same ulcer
(b) Prevention of other, new ulcers
(c) Prevention of limb deformity
All of these secondary outcomes to be measured at six months and
one year.
Tertiary outcomes
(a) Quality of life measures or other psychosocial or functional
measures, acceptability of intervention
(b) Days off work, school, or other tasks
(c) Cost of interventions
(d) Adverse events, either those sufficiently serious to stop inter-
vention, or minor ones reported by the participant
Search methods for identification of studies
Electronic searches
We searched the Cochrane Skin Group Specialised Register (April
2008) using the following terms:
lepros* or hansen* or leprae or leprotic
We searched the Cochrane Central Register of Controlled Trials
(The Cochrane Library Issue 1, 2008) using the following strategy:
#1(leprosy):ti,ab,kw
#2(hansen’s disease):ti,ab,kw
#3MeSH descriptor Leprosy explode all trees
#4(#1 OR #2 OR #3)
#5(SR-SKIN)
#6(#4 AND NOT #5)
The UK Cochrane Centre has an ongoing project to systemati-
cally search MEDLINE and EMBASE for reports of trials which
are then included in the Cochrane Central Register of Controlled
Trials. Searching has currently been completed in MEDLINE to
2003 and in EMBASE to 2005. Further searching has been un-
dertaken for this review by the Cochrane Skin Group to cover the
years that have not been searched by the UKCC.
We searched MEDLINE (OVID) from 2003 to April 2008 using
the search strategy in Appendix 1
We searched EMBASE from 2005 to April 2008 using the search
strategy in Appendix 2
We searched CINAHL (Cumulative Index to Nursing & Allied
Health Literature) from 1982 to October 2006 using the search
strategy in Appendix 3. This search could not be run in 2008 as
the Skin Group and the Norwegian Knowledge Centre for the
Health Services no longer have access to CINAHL.
We searched AMED (Allied and Complementary Medicine) from
1985 - to April 2008 using the following strategy:
1. exp leprosy/
2. leprosy.tw.
3. hansen’s disease.tw.
4. 1 or 2 or 3
We searched LILACS (Latin American & Caribbean Health Sci-
ences Literature) from 1982 to April 2008 using the search strat-
egy in Appendix 4
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Ongoing Trials
We searched the following ongoing trials registers on 10 th April
2008 using the terms ’lepro%’, ’leprosy’ and ’leprous’.
The metaRegister of Controlled Trials www.controlled-trials.com
The U.S. National Institutes of Health ongoing trials register
www.clinicaltrials.gov
The Australian and New Zealand Clinical Trials Registry
www.anzctr.org.au
The Ongoing Skin Trials register on www.nottingham.ac.uk/
ongoingskintrials
Searching other resources
References from published studies
We checked references from identified reviews and included stud-
ies.
Unpublished literature
We made an effort to identify unpublished and ongoing trials by
correspondence with authors and field experts. We had planned in
our protocol to search grey literature by searching SIGLE (System
for Information on Grey Literature in Europe) but neither we nor
the Skin Group had access to the system.
We contacted experts on tropical medicine and/or leprosy to check
our list of studies identified in the above searches and to ask if they
knew of any studies we had not found.
We searched the CD produced of all the papers published in the
main leprosy journals back to the 1920s (Leprosy Research Foun-
dation) “Compact disc of leprosy literature, 1913-1991”. Loma
Linda, California, USA, 1993.
Conference proceedings
Abstracts from conferences found in the International Journal of
Leprosy (1934 to 2005) were checked for further RCTs.
Hand searching
We handsearched the International Journal of Leprosy for reports
of trials from 1934 to 2005.
Language
We imposed no language restrictions when searching for publica-
tions.
Adverse events
We did not carry out a specific search for adverse events. Adverse
events bodies were not contacted. However, we screened for re-
porting of adverse events in the included randomised trials. In
future updates of this review we plan to screen other studies with
other designs for adverse events.
Data collection and analysis
Selection of studies
In the protocol we had stated that studies which were clearly not
randomised trials should be excluded. At least three of the studies
thatwe found stated that they hadused alternationwhen allocating
participants to groups. Studies using such methods are considered
to be quasi-randomised and are excluded from reviews whenever
randomised controlled trials are stated as the inclusion criterion
for type of design. However, treatments allocated alternately “are
in principle unbiased being unrelated to patient characteristics”,
under the assumptions that the underlying sequence in which par-
ticipants present to the study is random and that the procedure is
concealed to the persons that assign participants (Altman 1999).
Although such methods are possible to conceal, they are according
to theCochraneHandbook usually not concealed. If the allocation
procedure is open it is easy to manipulate by the person in charge.
This may result in a selection bias which in turn will threaten the
validity of the study. However, the same requirement of conceal-
ment of the allocation schedule relates to the use of random num-
bers tables (Chalmers 1999). Actually, failure to conceal is found
to be more important in predicting bias than other components
of allocation, such as the generation of the allocation sequence,
for instance by computer, random numbers table or alternation
(Higgins 2006).
The use of random numbers table makes it easier to conceal the al-
location, but theCochraneHandbook says nothing about whether
use of such tables usually is blinded when concealment is not re-
ported on. However, Pildal and colleagues who compared articles
that were unclear in their reporting of allocation concealment with
their protocols, revealed that only 16% of 96 studies in reality had
adequate concealment in their protocol (Pildal 2005). Except for
one study protocol that was rated as inadequate, all the others were
unclear also in their protocols. Consequently, in cases where it is
only stated that a random numbers table or alteration have been
used, wewill not be sure whether it was concealed or not and hence
resulted in a “true” randomisation. Therefore, we included those
studies that had used alternate allocation as well as those studies
that had used a possibly open random numbers table. We rated
the studies as unclear or inadequate with regard to concealment
accordingly.
We based inclusion or exclusion on the full article. Studies that
were clearly not randomised trials were excluded, others were as-
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sessed for eligibility by two authors (LMR, LF). Consensus with
persisting disagreement was to be adjudicated (by AB), but this
was not necessary. We kept a log of excluded studies with reasons
for exclusions.Wewrote to two trial authors formissing data about
study designs in March 2005 and March 2006, but received no
replies by March 2008.
Data extraction and management
Two authors performed the data extraction (LMR, LF), and inde-
pendently entered data onto a data extraction form. We resolved
discrepancies by consensus. One author (LMR) checked data ex-
traction forms and entered data into Review Manager (RevMan).
We were not blinded to the names of trial authors, journal or in-
stitutions.
Assessment of risk of bias in included studies
Weassessed the quality by evaluating the following components for
each included study. We categorised each component as adequate,
unclear, or inadequate. The quality components criteria were those
suggested by Juni 2001 since there is some evidence that these are
associated with biased estimates of treatment effect:
(a) the method of generation of the randomisation sequence;
(b) the method of allocation concealment - it was considered ’ad-
equate’ if the assignment could not be foreseen;
(c)whowas blinded/not blinded (participants, clinicians, outcome
assessors);
(d) howmany participants were lost to follow up in each arm (split
into post-randomisation exclusion and later losses if possible), and
whether participants were analysed in the groups to which they
were originally randomised (intention-to-treat).
In addition the quality assessment also included:
(e) degree of certainty that the participants have leprosy or com-
plications of leprosy;
(f ) baseline assessment of the participants for age, sex, duration
and severity of complications;
(g) aims, interventions (with details of how it was done) and out-
come measures clearly defined;
(h) use and appropriateness of statistical analyses.
Two authors performed the quality assessment and independently
judged the components on the quality assessment form (LMR,
LF). We resolved disagreements with a third author (AB). We
described the quality of each study based on a summary of these
components. We also assessed the overall quality of the included
studies. Note that the nature of interventionsmade it impossible to
meet all criteria adequately, i.e. blinding of providers. Two authors
(LMR,LF) recorded the information in Table 1
Measures of treatment effect
Two authors (LMR, LF) analysed the data with input from a statis-
tician. We calculated standardised mean differences for continu-
ous outcomes (with 95% confidence interval). We expressed the
results as risk ratio (RR) and 95% confidence intervals (CI) for
dichotomous outcomes.
Assessment of heterogeneity
We assessed clinical heterogeneity by looking at the populations,
concurrent treatment, settings and outcome measures. We used
the I2 test to assess statistical heterogeneity. I2 values of 25% or less
were considered to indicate low heterogeneity, and values of 75%
or greater were considered high heterogeneity (Higgins 2006), and
the Chi-square test where we considered a significance level of p
< 0.1 to indicate heterogeneity.
Data synthesis
We presented the results of the trials with presence of clinical
heterogeneity in a narrative. In future updates, when trials are
regarded to be sufficiently clinically or methodologically similar,
but statistical heterogeneity is present, we will pool the results by
using a random effects model.
Subgroup analysis and investigation of heterogeneity
We did no sub-group analyses. As no trials were combined, it was
irrelevant to investigate reasons for heterogeneity. In future up-
dates of this review we will look for sources of heterogeneity if
appropriate (i.e. country of origin, leprosy classification, interven-
tion, compliance, outcome assessment).
Sensitivity analysis
We did no sensitivity analyses. If, in future updates of this review,
we pool trials, we will re-analyse the data using fixed or random
effects model as appropriate. We will also do sensitivity analyses
if appropriate to examine the effects of including or excluding
subgroups based on participant factors, treatment factors or study
factors.
R E S U L T S
Description of studies
Results of the search
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In total, the search found 854 citations to potentially relevant
trials. Thirty-five citations were retrieved in full text and eight were
included. The search did not reveal any ongoing trials.
Included studies
We included 8 trials with a total of 557 participants. All included
trials were small and had included between 43 and 110 people
affected by leprosy. The age range of participants in four studies
was 18 to 70 years, two studies reported an average age of 42 and
46, while two studies did not report information on the age of the
participants. All included studies were published between 1982
and 2004. One study had three arms and one study reported on
two separately conducted trials (multicenter study). The initial as-
sessment and baseline reporting of leprosy and damage to periph-
eral nerves was recorded in varying details, as was the reporting
of outcome measurements and the results. The follow-up period
varied from one month to one year.
All trials reported the primary outcome of healing of existing ul-
cers, measured either as percentage healed or number of ulcers
healed. The other primary outcome, prevention of limb deformity
was not reported in any of the included trials. All participants had
skin damage at trial entry. Typical outcome measures were:
• number of ulcers healed;
• size of ulcers or reduction of ulcer size;
• number of new ulcers;
• ulcer free at one year;
• ulcers not healed;
• ulcers fully healed.
None of the included trials measured the outcomes we had listed
as secondary or tertiary outcomes for our review.
The studies took place in India, Indonesia, Mexico and Ethiopia.
All studies included participants affected by leprosy with plantar
ulcers (simple ulcers, trophic leprosy ulcers or with anaesthetic
feet), and two studies also included people with ulcers on hand
and elbow (Salazar 2001) and ulcers on palm and gluteal ulcers
(Bansal 1993). Most participants had simple plantar ulcers, but
some studies also included participants with infected ulcers i.e.
treated with antibiotics. Three studies were hospital (in-patient)
based (Bansal 1993; Bhatia 2004; Söderberg 1982), while five were
based at out-patient clinics (Overbeek 1991; Pring 1982; Salazar
2001; Seboka 1998; Walton 1986).
Three trials evaluated zinc tape, two trials topical phenytoin, and
one trial topical ketanserin. One trial evaluated canvas shoe and
another plaster of Paris double-rocker plaster shoe. Co-interven-
tions varied and included bed-rest, ulcer care, education, ulcers
cleaned with benzalkonium chloride, soaking and drying of feet.
Two trials (Söderberg 1982; Walton 1986) had statements on the
social acceptability of the intervention but reported no actual find-
ings in this regard. One trial had asked the participants which of
the interventions they preferred and had also made a simple cost
analysis. Two studies reported on whether there were harmful ef-
fects (Bhatia 2004; Salazar 2001). We have included details of all
the studies in the Characteristics of included studies.
There was great diversity (or heterogeneity) between interventions
and methods used to measure outcomes in the trials. Two studies
(Bansal 1993; Bhatia 2004) used similar interventions and out-
come measures. Bansal and Bhatia also restricted the participants
to bed rest. The rest of the studies used different interventions and
comparisons and could therefore not be pooled. We were unable
to extract data from the study comparing adhesive zinc tape with
gauze soaked in Eusol, so we described the results from the study
(Söderberg 1982).
Excluded studies
We excluded 32 studies, the main reason for exclusion being that
they were not randomised trials. The table of the Characteristics
of excluded studies lists the studies that did not meet the inclusion
criteria.
Risk of bias in included studies
In the included trials it was often difficult to make out whether
the participants had one or several ulcers. When the allocation is
done on an individual level and the participants have several ul-
cers, it means that one person will contribute several times in the
analysis. This represents a unit of analysis error if not corrected for.
In turn, this might lead to an over-estimate of the effect because
the intra-variance between healing of ulcers on the same person
may be smaller than the inter-variance of healing of ulcers between
individuals. In three studies the number of participants were the
same as the number of ulcers, four studies may have had a unit of
analysis error (but they all had results that were insignificant sta-
tistically), while the fifth used two treatments for each participant,
one for each ulcer, but it is unclear how this was analysed (Bhatia
2004).
The methodological quality of the trials was generally poor; only
three of the trials were scored as having moderate overall quality
while all the others were rated as low. How each trial scored on
each quality component can be found in Table 1.Most of the trials
were characterised by inadequate and unclear reporting. Only the
interventions were reasonably well described; it seemed like both
intervention and control groups were treated equally in all other
respects. None of the studies reported on sample size calculations.
Sample sizes ranged from 38 to 110, with a mean of 67 and a
median of 57. Four studies most probably did do analysis by in-
tention-to-treat, one study lost one participant in the experiment
group, one study was unclear as to who was included in which
analysis (Bhatia 2004) and two studies clearly did not use inten-
tion-to-treat analysis (excluded lost participants from analysis).
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Allocation
All studies gave inadequate description of the randomisation pro-
cedure. Three studies stated only that the participants had been
randomly assigned (Pring 1982; Salazar 2001; Seboka 1998), and
four studies hadused alternate assignment (Bansal 1993;Overbeek
1991; Söderberg 1982;Walton 1986). One study had used a table
of random numbers for the assignment procedure (Bhatia 2004),
but the authors are unclear as to whether the randomisation itself
was concealed or whether it applies to the providers throughout
the study: “After breaking the code at the end of the study, it was
found that each group had 15 patients”. None of the others spec-
ified whether the procedure had been concealed. Consequently,
the trials very likely suffer from a lack of control of selection bias.
We assessed base-line measurements as indications of similarity
of the groups and judged them as adequate in three of the eight
studies (Bansal 1993; Bhatia 2004; Salazar 2001). InWalton 1986
it is stated that base-line measurements were comparable but only
the age of participants in the two groups is provided (which dif-
fered by about eight years), so we rated this component as unclear
accordingly. In the other studies base-line values were either not
provided and therefore rated as unclear or deemed as showing di-
versity between groups and therefore rated as inadequate.
Blinding
Two studies reported blinding of outcome assessors explicitly
(Bansal 1993; Bhatia 2004). None of the other study reports men-
tioned blinding of assessors, so for lack of sufficient details we
rated these studies as unclear regarding this component.
Other potential sources of bias
Follow-up and exclusions
It was not easy to deduce follow-up rates but if accepting no men-
tion in the text and no signs of attrition in tables, as a 100% fol-
low-up, the follow-up rates ranged from 47% (Overbeek 1991)
- 100% (Bansal 1993; Bhatia 2004; Pring 1982; Salazar 2001;
Seboka 1998). The follow-up in Söderberg 1982 was unclear.
Effects of interventions
Of the 8 studies included, with a total of 557 participants, only
2 compared the same interventions and also had comparable out-
comes. We present the results with reference to the original ques-
tions posed by the review. All trials reported on the first of the
primary outcomes we had stated for the review, that of ’healing of
existing ulcers’.
Can any intervention prevent/heal secondary damage
to the skin in persons with leprosy, for example self-
care, dressings or appropriate footwear?
Comparisons between dressings
We included three studies on zinc tape, but they all had different
comparisons and had reported differently on the outcome mea-
sures for wound healing, so pooling of results was not meaningful
(Overbeek 1991; Söderberg 1982; Walton 1986).
Zinc tape versus magnesium sulphate/glycerin
Walton et al reported a small trial conducted in India (Walton
1986). Forty-three people affected by leprosy with plantar ulcers
were allocated to either zinc tape (22 participants) or gauze soaked
in magnesium sulphate ointment (21 participants). The partici-
pants had one ulcer each. Outcome measures were number of ul-
cers healed and mean reduction of ulcer area (not reported here).
There was only 65% follow-up for both groups (14 participants
returned to clinic in each group after 1month). Four ulcers treated
with adhesive zinc tape and two in the control group healed com-
pletely. The RR for ulcers healed at one month for zinc tape com-
pared with magnesium sulphate was RR 2.00 (95% CI 0.43 to
9.21 Analysis 1.1), although this is a clinical effect the study failed
to demonstrate a statistical significant difference between zinc tape
and gauze soaked inmagnesium/glycerin regarding the promotion
of ulcer healing.
Zinc tape versus gauze soaked in Eusol (Edinburgh
University solution of lime)
Söderberg et al conducted a multi-centre trial in India (Söderberg
1982).Ninety people affected by leprosy with 128 plantar ulcers in
2 hospitals were separately alternately allocated to either adhesive
zinc tape or ordinary gauze dressings soaked in Eusol. One centre,
Mangalore, had 30participants; 15 in each groupThe other centre,
Polambakkam, had 60 participants; 33 in the zinc tape group and
27 in the Eusol group. The outcome measure was time to heal in
days and the follow-up time was one to twomonths. InMangalore
it took about 20 (CI 18 to 23) days on average for superficial
ulcers to heal in the zinc tape group versus about 30 days (CI 27
to 33) to heal in the gauze group. For deep ulcers it took 35 (CI
30 to 40) days to heal in the zinc-tape group, while in the gauze
group about 44 (CI 22 to 61) days were needed for healing. In
Polambakkam the average number of days to heal in the zinc tape
group for superficial wounds were about 13 (CI 9 to15) days and
23 (CI 15 to 28) days in the gauze group. For deep ulcers it took
17 days (CI 12 to 20) in the zinc tape group and 30 (CI 12 to
63) days in the gauze group. The authors of the trial state that all
the participants in Mangalore wore shoes, while eighteen of the
participants in Polambakkam wore shoes. We do not know if this
explains the heterogeneity in the results.
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The average healing time was shorter for ulcers treated with zinc
tape compared to gauze treated ulcers, but according to the au-
thors, this difference was only statistically significant in Polam-
bakkam, which was the larger group. The authors state further
that zinc tape has the following advantages: low cost, easy appli-
cation and convenience, also it can be worn under shoes without
causing pressure and is socially more acceptable as no bandages
are needed. However, the authors had not asked any of the users
about their preferences.
Zinc oxide tape versus povidone iodine
In Indonesia, Overbeek et al conducted a trial where they com-
pared zinc oxide tape with gauze soaked in 10% povidone iodine
(Overbeek 1991). A total of 56 people were recruited and alter-
nately allocated into 2 groups, (in 10 different clinics); the pre-
liminary size of groups is unknown. During the investigation 18
participants were lost to follow-up and 38 people were included in
the analysis; 26 in the zinc oxide tape and 12 in the iodine group.
The primary outcome measure was the mean difference between
groups in the reduction of the ulcer area.
The secondary outcome was mean surface area reduction of the
ulcers between subgroups of high (walking > 2.2 km per day or
> 4.07 hours work per day) and low (< 2.2 km per day or <
4.07 hours work per day) activity level of the participants in both
groups. There was no information on whether numbers of ulcers
were the same as numbers of persons. The follow-up was six weeks.
The authors found no statistical significant difference between the
groups, although the ulcer healing was in favour of zinc oxide
tape: SMD0.29 (95%CI -0.40, 0.97 Analysis 3.1). Also regarding
the difference in healing, depending on high and low activity, the
healing was slightly better for the zinc tape participants with low
activity compared to those with high activity, and slightly better for
iodine participants with low activity compared to those with high
activity (not analysed here because of the very small numbers).
Comparison between topical agents
One study of moderate quality compared the use of topical ke-
taserin (Salazar 2001) with clioquinol cream or zinc paste.
Topical ketanserin versus clioquinol cream or zinc paste
In Mexico, Salazar conducted a trial where the intervention group
(n=33) was treated with topically applied ketanserin gel (2%) and
the controls (n=33) were treated with topically applied clioquinol
cream or zinc oxide paste (Salazar 2001). The outcome measure
was the number of completely healed ulcers. All persons had one
ulcer each and there was no loss to follow-up. At three months
follow-up, 37% of the ulcers in the intervention group had healed
compared with 6% for the controls; the RR was 6.00 (95% CI
1.45 to 24.75Analysis 4.1), i.e. the study demonstrated a statistical
significant difference between the two groups as to promoting
ulcer healing.
Comparison between topical agent versus dressing
Two studies compared phenytoin versus saline dressing. These two
studies were not pooled because of statistical heterogeneity (Bansal
1993; Bhatia 2004).
Topical phenytoin versus saline dressing
Two Indian studies with a total of 145 participants reported the
effect of topical phenytoin comparedwith normal saline on trophic
ulcers (Bansal 1993; Bhatia 2004). Bhatia et al used 3 comparison
groups, with 15 participants in each. The total number of fully
healed ulcers were the same for both intervention groups in this
study, but measured as the mean percentage reduction of ulcer
size, there were nevertheless some differences between the 2% and
4% phenytoin groups, but they were not statistically significant.
In Bansal et al ten participants had two ulcers each, in which case
one ulcer was treated with phenytoin and the other with normal
saline. It is unclear if the trialists adjusted for this in the analyses.
The ulcers in the Bansal study were of “varying chronicity”, while
in Bhatia they had “less than three months duration”, i.e. acute
ulcers. All participants in theBhatia andBansal studies hadbedrest.
The outcome measure was the mean percentage of ulcer volume
reduction. Follow-upwas done at four weeks for all participants. In
the Bhatia study it is unclear whether all participants were included
at the end of the study. Bhatia’s study gave an estimate of SMD -
2.34 (95% CI -3.30 to -1.39 Analysis 5.1). Bansal’s study gave an
estimate of SMD -0.79 ( 95%CI -1.20 to 0.39 Analysis 5.1). Both
studies demonstrated a statistically significant difference between
the effect of topical phenytoin versus saline dressing, favouring
phenytoin.
Trials of footwear
The two studies comparing footwear were too clinically heteroge-
neous to be pooled. One study compared canvas shoe with PVC-
boot (Seboka 1998) and the other study compared double rocker
plaster shoe with padded below-knee plaster (Pring 1982). The
studies varied in time of follow-up from six weeks to a year.
Canvas shoe versus PVC-boot
In rural Ethiopia, Seboka et al conducted a study involving 110
farmers affected by leprosy (Seboka 1998). The participants had
either one or more plantar ulcers or had a scar of a healed ulcer.
They were allocated to either canvas shoe group (52) or PVC boot
(“Wellington boot”) group (58). The outcomes were the number
of participants being ulcer free and number of particpants hav-
ing ulcers not healed, acceptability of the footwear and footwear
condition. The study had a one-year follow-up and one person
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in the canvas shoe group was lost to follow-up. There was no sta-
tistically significant difference between the two groups when it
came to participants being ulcer free at one year; (RR 1.16; 95%
CI 0.77 to 1.74 Analysis 6.1). The authors reported that no new
ulcers developed during study period in either group. The RR for
those having ulcers not healed at one year was 0.52 (95% CI 0.15
to 1.75 Analysis 6.2), favouring the canvas shoe group, although
this result was not statistically significant. They also reported that
PVC boots were much more durable than the canvas shoes, but
they could become very hot. Eighty percent of the farmers rated
PVC boots as “excellent” for social acceptability and suitability for
work. The canvas shoes were rated as socially acceptable, but not
rated as highly suitable for work.
Double-rocker plaster shoe versus below-knee plaster
Pring’s Indian study reported a comparison of a traditional below-
knee plaster with a padded, moulded double-rocker plaster shoe
(Pring 1982). Forty-seven people affected by leprosy with a total
of 55 plantar ulcers were randomly allocated to both groups. In
addition dressings with magnesium sulphate, glycerine and acri-
flavine were applied to all ulcers and removed after six weeks, at
follow-up. Also, at the time of application and removal of plasters
all participants were given health education on foot care (daily
foot inspection, foot soaking and scraping, and the importance
of the regular wearing of soft-lined chappals. Outcome measures
were ulcers fully healed, ulcers nearly healed and ulcers failed to
heal. The authors found that of the 31 ulcers treated with plaster
shoe, 18 were fully healed after 6 weeks; 8 were nearly healed and
5 failed to heal. Of the 24 ulcers treated by below-knee plaster, 18
were fully healed, 3 nearly healed and 3 had failed to heal after 6
weeks. The authors state that the plaster shoe was more accept-
able to the person affected by leprosy and cheaper to apply. The
statistical analysis of ulcers fully healed showed (RR 1.29; 95%
CI 0.89 to 1.88 Analysis 6.1) in favour of the below-knee plaster
group; nearly healed (RR 2.06; 95% CI 0.61 to 6.96 Analysis 6.2)
in favour of the double rocker plaster shoe group; and for ulcers
not healed (RR 0.78; 95% CI 0.21 to 2.93 Analysis 6.3) favour-
ing the plaster shoe group, i.e. no statistical significant differences
between groups were demonstrated.
We did not find any randomised trials that evaluated the effect
of self-care, other educational interventions or rest versus activity.
No trials reported prevention of limb deformity as an outcome.
Which of the interventions are the most effective?
We did not find any studies that directly compared different treat-
ments, except for the comparisons reported above, so we cannot
say whether for instance zinc tape is more effective than topical
phenytoin.
Do these interventions reduce social stigma and lead
to better quality of life?
Only one study reported that canvas shoes were seen as socially
acceptable to their users, although PVC boots were perceived as
more suitable for work (Seboka 1998). Plaster shoe is more ac-
ceptable than below-knee plaster (Pring 1982 ). We did not find
any studies that reported on quality of life.
Are any interventions harmful?
Three studies, one on topical ketanserin versus clioquinol cream
or zinc paste (Salazar 2001), one on topical phenytoin versus saline
dressing (Bhatia 2004) and the third study comparing zinc tape
to gauze with Eusol (Söderberg 1982) reported that no adverse
effects of the treatment were observed, while the trialists did not
report adverse effects in the other studies.
D I S C U S S I O N
Summary of main results
We found and included eight studies with a kind of randomisa-
tion procedure for allocating participants to groups. Although the
three studies that compared zinc tape tomore traditional dressings
found some benefit, none of these had a statistically significant
effect. Topical ketanserin had a better clinical effect on wound
healing than clioquinol cream or zinc paste. The two studies that
compared topical phenytoin to saline dressing demonstrated a sta-
tistically significant effect in both studies. Canvas shoes were not
much better than PVC-boots and double rocker shoes did not pro-
mote healing more than below-knee plasters. None of the studies
reported any harms caused by the treatment, except for a general
statement by the trial authors of the plaster study that plasters in
general may result in osteoporosis of bones in the foot caused by
lack of use, which in turn may result in fractures when plaster is
removed.
Overall completeness and applicability of
evidence
The studies we identified were not sufficient to address all of the
objectives of the review. Our objective was to investigate whether
there were interventions that could prevent or treat secondary
damage to the skin in people with leprosy, for example self-care,
dressings or appropriate footwear. We found eight studies alto-
gether of seven different interventions, so the lack of replication of
studies in itself limits the reliability and applicability of results. As
none of the comparisons were done crosswise we can draw no con-
clusions as to which of the interventions were the most effective.
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Likewise, none of the studies investigated whether the interven-
tions had the potential to reduce social stigma and lead to better
quality of life. We did not find any trials that evaluated the effect
of self-care or educational interventions.
Quality of the evidence
The studies that we included did not allow any robust conclusion
regarding the objectives they addressed. There were several reasons
for this. Overall, it was difficult to assess the validity of the results
of the studies, due to the lack of clear reporting of methods and
data in general and of the allocation process in particular. We
do recognise that these studies were reported at a time when the
importance of a full description of the allocation process had not
been much focused on in contemporary literature. In fact, only
one of the studies (Bhatia 2004) would have had a chance to
report according to previous (Begg 1996) or current guidelines for
reporting clinical trials (Moher 2001).
The empirical evidence for whether one can suppose that the al-
location procedure has been concealed or not in the real setting,
when not reported on, is conflicting (Pildal 2005). For example, in
one study, authors of 40 rheumatology articles published in 1997/
1998, in which the statement regarding allocation concealment
was unclear, were asked by means of a questionnaire whether they
in fact had concealed the allocation procedure and in 78% of 32
trials, the allocation process was reported by their trialists to have
been concealed (Hill 2002). In a study by Deveraux 2004, 98 ar-
ticles reporting trials in 29 journals in the period 1997 to 1998,
were assessed for reports of concealment of allocation. They found
54 out of 56 (96%) trials with an unclear allocation procedure
in the published documents were reported by the researchers in a
telephone interview to actually have used concealment when allo-
cation to groups had been done. However, a third study collected
102 authorised protocols of randomised controlled trials for the
years 1994 and 1995 from two districts in Denmark (Pildal 2005).
They were used for verification of whether concealment had been
done or not when the statement in their corresponding publica-
tions was unclear. The authors found that only 16% (15/96) of
the publications not reporting concealment had stated in the pro-
tocol that this would be done. Compared to using the authors’
self-report to determine the real occurrence of concealment, using
the protocols for verification of actual use, seems more credible.
Accordingly, we consider that the studies included in our review
that did not report on allocation concealment, most likely did not
conceal the allocation process, which in consequence may have led
to selection bias.
One included study clearly used blinded assessors to assess degree
of ulcer healing and one study most likely used blinded assessors.
Due to the small sample sizes, the conclusions in all trials may be
subjected to the possibility of both erroneously seeing a difference
when there is none (type I error) and erroneously not seeing a
difference when there is one (type II error), as the risk of both errors
increases with small samples. Moreover, only one comparison was
replicated so the other comparisonswere all only done in one study.
As demonstrated in two of the studies (Bansal 1993;Bhatia 2004)
there seems to be a lack of consensus of how to measure wound
surface area. This may result in less reliable, imprecise and non-
comparable measures. A complete healing of wounds would be
easier to measure objectively than surface area and also would be
the outcome of greatest interest to people with leprosy as well as to
healthcare providers. Others have recommended that investigators
measure time to healing, analysed as a life table or by survival
analysis (Palfreyman 2006). For some of the trials the follow-up
time was only four weeks and this might be somewhat short -
results from one of the included trials indicate that ulcers may
need a longer healing period.
Shaw and colleagues conducted a systematic review on the clin-
ical effect of topical phenytoin on wound healing (Shaw 2007).
They too found that most papers failed to describe randomisation,
treatment allocation and blinding techniques adequately. The au-
thors included prospective controlled trials or RCTs and carefully
concluded that topical phenytoin might have a positive effect on
wound healing in a variety of wounds (including leprosy).
Potential biases in the review process
Overall, the inadequate reporting of the trials is themost important
threat to the validity of the review process. This may have led to
misunderstandings during the critical appraisal of the studies and
of our descriptions and evaluations.We have not assessed potential
publication bias. Since several studies with no significant effect
and also with very few participants, have been published, this is
an indicator that suggests that publication bias in this case is not
very likely. However, we cannot know if we have identified all
relevant studies. The trials we found were small, so similar sized
trials may have been done and not been reported. The authors
of the included trials may have done additional trials. Also, the
countries in which the trials were done, are not well represented
in the databases we searched (except for LILACS). For example,
Indian literature may have escaped our searches.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Which of the interventions are the most effective?
Topical ketanserin may be more effective than clioquinol cream
or zinc paste and topical phenytoin may be more effective than
saline dressing in ulcer healing. However, this is based on very
weak evidence, for topical ketanserin only one study tested the
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comparison and for phenytoin the summary analysis of two studies
did not show a very clear effect. For the other comparisons the
results were equivocal. Whether the interventions reduce social
stigma and lead to better quality of life were not investigated in
any of the trials. Three studies reported that no side effects of
treatment were observed.
Implications for research
The disabilities resulting from sensory nerve damage in leprosy,
have a serious impact on the quality of life of the persons affected.
Not only is it potentially disabling, but since leprosy still carries
social stigma, visible signs of the presence of the disease in the per-
son concerned may cause distress and prejudice. Research should
not be neglected, as there is a need for high quality research in
the field of ulcer prevention and treatment in people with leprosy.
However, research projects in themanagement of skin changes and
ulcers in leprosy need to be improved regarding methodological
quality, including setting a standard in identifying suitable out-
come measures. An important tool to attain improved quality is
to follow the current standards for design and reporting of ran-
domised controlled trials.
In particular this research should aim to compare:
(a) different types of dressings, including dry dressings;
(b) different types of topical agents;
(c) topical agents versus dressings;
(d) different types of footwear;
(e) different self-care and educational programmes.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bansal 1993
Methods Type of trial: Quasi-randomised controlled trial
Study duration: Four weeks
Allocation procedure: Participants assigned alternately.
Blinding of participants and clinicians not applicable. Outcome assessor was independent
to study groups
Participants Country and setting where study took place: In-patients (hospital) in India
Participants: 100 people (14 females) affected by leprosy having difficult ulcers of varying
chronicities.
Inclusion criteria: Trophic leprosy ulcers
Exclusion criteria: People affected by leprosy with other systemic diseases or gross cellulitis
Interventions Intervention in experimental group (n=50): topical phenytoin powder (daily)
Intervention in control group (n= ): saline (daily)
Co-interventions both groups: All necrotic tissue and slough was removed by meticulous
debridement, and the ulcers were cleansed with sterile swab. All participants continued
their anti leprosy treatment and appropriate antibiotics. A strict bed-rest regimen and a
uniform dietary regimen were followed for all participants
Outcomes Healing of ulcer.
Notes In the cases where the participants had two ulcers one ulcer was treated with phenytoin
and the other with normal saline. Unclear if ten participants with two ulcers were included
in the overall outcome measurement
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk C - Inadequate
Bhatia 2004
Methods Type of trial: Randomised controlled trial
Study duration: Four weeks
Allocation procedure: Table of random numbers.
Double-blind. Outcome assessor was blinded to study groups.
Participants Country and setting where study took place: Hospital (in-patients ) in India.
Participants: 45 people (14 females) affected by leprosy aged 18 to 60 years with acute
leprosy trophic ulcers (i.e. less than three months duration). BL and LL type of leprosy
(Ridley Jopling classification).
Inclusion criteria: Simple ulcers
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Bhatia 2004 (Continued)
Exclusion criteria: Anemia, hypoproteinaemia, chronic use of immunosuppressant medi-
cation, immobility, folate deficiency, those receiving oral phenytoin, a history of adverse
effects caused by phenytoin, any other systemic disease and pregnant or lactating females
Interventions Intervention in experimental group 1 (n=15): Topical 2% phenytoin sodium suspension
(Daily up to four weeks)
Intervention in experimental group 2 (n=15): Topical 4 % phenytoin sodium suspension
(Daily up to four weeks)
Intervention in control group (n=15 ): Saline dressing (Daily up to four weeks)
Co-interventions all groups: All necrotic tissue and slough was removed. The ulcers were
cleansed with sterile swab. All participants continued to receive their anti leprosy treatment
and appropriate antibiotics. Strict bed rest and uniform dietary regimen
Outcomes Healing of ulcer.
Local and systemic adverse effects (monitored by clinical assessment and interrogation of
the participant)
Notes Simple ulcers were defined as one involving only skin and subcutaneous tissue and having
no bone involvement
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Overbeek 1991
Methods Type of trial: Quasi-randomised controlled trial
Study duration: Six weeks
Allocation procedure: Alternation per out-patients clinic.
Information on blinding of participants, clinicians and outcome assessor not given. 32%
of the participants were lost to follow up. Groups were not similar at baseline
Participants Country and setting where study took place: Out-patients clinics in Indonesia.
Participants: 56 people affected by leprosy with plantar ulcers. Divided in groups by high
or low activity level (walking > 2.2 km per day or > 4.07 hours work per day was defined
as high activity). Of the 38 participants that were followed through the study 32 were men
(6 females) and the average age was 42 years.
Inclusion criteria: People affected by leprosy with simple plantar ulcers.
Exclusion criteria: People affected by leprosy with ulcers that were infected, were necrotic
or if there were signs of osteomyelitis
Interventions Intervention in experimental group (n=26): Zinc oxide tape
Intervention in control group (n=12 ): Povidone-iodine 10%
Co-intervention in experimental group: Povidone-iodine10%
Outcomes Healing of ulcer.
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Overbeek 1991 (Continued)
Notes Published in Dutch. We had data-collection and quality-assessment checked by Dutch
native
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk C - Inadequate
Pring 1982
Methods Type of trial: Randomised controlled trial
Study duration: Six weeks
Allocation procedure: Information not given in paper.
Blinding of participants and clinicians not possible. Outcome assessor was probably not
blinded to study groups
Participants Country and setting where study took place: Outpatients (majority) in India (or Nepal).
Not clear information in paper.
Participants: 47 people (gender not given) affected by leprosy, 55 ulcers.
Inclusion criteria: Simple plantar ulcers. Informed consent.
Interventions Intervention in experimental group (n=31 ulcers): Padded moulded double-rocker plaster
shoe
Intervention in control group (n=24 ulcers ): Padded below-knee plaster
Co-interventions both groups: Intensive health education on foot care (daily foot inspec-
tion, foot soaking and scraping and the importance of regular wearing of soft-lined chap-
pals)
Outcomes Healing of ulcers.
Notes Participants were randomised, but results given only for ulcers (not equally distributed
between groups).
Simple plantar ulcers were defined as ulcer on the plantar surface of the anaesthetic foot
which did not involve either the underlying bone, joint or tendon
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
19Interventions for skin changes caused by nerve damage in leprosy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Salazar 2001
Methods Type of trial: Randomised, controlled trial
Study duration: Three months
No information given on allocation procedure.
No information on blinding of participants, clinicians or outcome assessor. Baseline and
outcome measures documented by the use of photographs
Participants Country where study took place: Mexico (probably). Outpatients examined every two
weeks.
66 people (30 females) affected by leprosy with skin ulcers. Ulcers were secondary to
vascular, bony, infectious, neurological or traumatic causes.
Inclusion criteria: Participants should have had supervised anti leprosy treatment for at least
one year, negative bacilloscopy last 12 months, aged between 18 and 70 years and grade II
and III ulcers according to Wagner’s classification, present for more than 6 months.
Exclusion criteria: Participants with ulcers with additional infections, positive bacilloscopy,
erythema nodosum leprosum, a leprosy reaction, previous thrombotic episodes or lumbar
sympathectomy, treatment with diuretics, those with obvious edema of the lower limbs,
arterial hypertension, cardiac disease, renal or liver failure
Interventions Intervention in experimental group (n=33): Topically applied 2% ketanserin gel every 12
hours.
Control group intervention (n=33): clioquinol 3% or zinc oxide paste every 12 hours.
Co-intervention both groups: Ulcers cleaned with benzalkonium chloride
Outcomes Healing of ulcers.
Side effects classified as minimum, moderate and severe.
Notes Insufficient reporting.
The Wagner classification system of wounds:
grade 0 = no open lesion;
grade 1 = superficial ulcer without penetration to deeper layers;
grade 2 = ulcer penetrates to tendon, bone, or joint;
grade 3 = lesion has penetrated deeper than grade 2 and there is abscess, osteomyelitis,
pyarthrosis, plantar space abscess, or infection of the tendon and tendon sheaths;
grade 4 = wet or dry gangrene in the toes or forefoot;
grade 5 = gangrene involves the whole foot or such a percentage that no local procedures
are possible and amputation (at least at the below the knee level) is indicated.
57 of ulcers were located on foot/foot soles.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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Seboka 1998
Methods Type of trial: Randomised controlled trial
Study duration: One year
Allocation procedure not given in the paper.
Blinding of participants and clinicians not possible. Unclear if outcome assessor was blinded
to study groups. One person lost to follow up in experimental group
Participants Country and setting where study took place: Rural area in Ethiopia.
Participants: 110 male farmers.
Inclusion criteria: One or more plantar ulcer(s), or had scar of a healed ulcer. Loss of
sensation as tested by a 10 g monofilament
Interventions Intervention in experimental group (n=52): Canvas shoe
Intervention in control group (n=58 ): PVC boot
Outcomes New ulcer(s)
Healing of ulcers.
Acceptability of the footwear determined by a standard set of questions
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Söderberg 1982
Methods Type of trial: Quasi-randomised controlled trial
Study duration: Two months
Allocation procedure: Selection on a random alternate basis.
Blinding of participants and clinicians not possible. Unclear if outcome assessor was blinded
to study groups
Participants Country and setting where study took place: Two hospitals (Mangalore and Polambakkam)
in India (in-patients).
Participants: 90 people, 18 females, (with a total of 128 ulcers, 86 ulcers in Mangalore and
42 in Polambakkam) affected by leprosy with non-complicated ulcers on the soles of the
feet. Disability grade 1 and 2 (WHO classification)
Interventions Intervention in experimental group (n=48): Adhesive zinc tape (zinc oxide 30%), tape
changed daily when wound secretion was excessive, then less frequently.
Intervention in control group (n= 42): Gauze sponge soaked with Eusol and covered with
bandage, new dressings as for experimental group.
Co-interventions both groups: Soaking and drying of feet.
All participants in Mangalore (n=60) used shoes. Eighteen of the 30 participants in Polam-
bakkam used shoes
21Interventions for skin changes caused by nerve damage in leprosy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Söderberg 1982 (Continued)
Outcomes Healing of existing ulcer, reported separately for deep and superficial wounds.
Cost, application, convenience, socially acceptability (but no information on how this was
measured)
Notes Results were inaccurately reported
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk C - Inadequate
Walton 1986
Methods Type of trial: Randomised, controlled trial (possibly quasi-randomised)
Study duration: One month
Allocation procedure: Consecutive cases were randomly allocated to intervention and con-
trol group
Blinding of participants and clinicians not possible. Unclear if outcome assessor was blinded
to study groups. 35% loss to follow up
Participants Country and setting where study took place: Outpatient clinic in India. Rural area, farmers
working in the fields and sugar plantations.
43 participants aged 25 to 58 years, gender not given. Included in studywere people affected
by leprosy who were both lepromatous or non-lepromatous with “simple” plantar ulcers.
The study groups were comparable in terms of distance walked each day, duration of the
ulcer, sex and classification of leprosy. The zinc tape group was rather younger. Information
about the wearing of shoes is not given in the paper
Interventions Intervention in experimental group (n=22 ulcers): zinc tape 2 cm wide strips
Intervention in control group (n=21 ulcers): dressings with gauze soaked in a paste of
magnesium sulphate and glycerin with proflavin and benzalkonium chloride (MGSA).
Co-interventions both groups: all ulcers were cleaned with antiseptic solution of cetrimide
followed by ethanol. Routine debridement of the edges of ulcers. Each participant was
supplied with sandals made with micro-cellular rubber soles and individually tailored arch
support
Outcomes Change in area of wound.
Healing of ulcer.
Fourteen participants from each group returned to clinic after one month (65%)
Notes Simple ulcers were defined as: those involving only skin and subcutaneous tissue, not
infected, and containing no necrotic bone or fibrous tissue
Risk of bias
Bias Authors’ judgement Support for judgement
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Walton 1986 (Continued)
Allocation concealment (selection bias) High risk C - Inadequate
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abera 2003 Study design criteria not met. Survey.
Abera 2003b Study design criteria not met. Survey.
Balkin 1997 Study design criteria not met. Case report.
Benbow 2001 Study design criteria not met. Descriptive study.
Bogaert 1990 Study design criteria not met. Controlled before and after study
Chauhan 2003 Particiapants diagnosed diabetes, leprosy and other conditions in a mix
Cross 1995 Probably not randomised trial. We wrote to the author in March 2005, but have not received any reply byMarch
2008
Cross 1996 Probably not randomised trial. We wrote to the author in March 2005, but have not received any reply byMarch
2008
Cross 2001 Not randomised trial
Dowlati 2002 Intervention criteria not met. Randomised trial of BCG vaccination
Ethiraj 1995 Study design criteria not met. Prospective cohort with concurrent controls
Fritschi 1959 Study intervention criteria not met. Quasi-randomised trial with intervention oral Hydergine
Jha 2002 Study intervention criteria not met. Randomised trial of punch grafting which is a surgical procedure
Kaada 1988 Study design criteria not met. Before and after study.
Kumar 1985 Study design criteria not met. Prospective cohort with concurrent controls
Kumar 1986 Study design criteria not met. Before and after study.
Laxmi 1992 Study design criteria not met. Survey.
Liangbin 2003 Study design criteria not met. Before and after study.
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(Continued)
Maney 1958 Study intervention criteria not met. Intervention was Hydergine (0.3 mgm) injected intra-arterially. Controlled
clinical trial
Mathew 1999 Study design criteria not met. Before and after study.
Matthews 1978 Study design criteria not met. Survey.
Menezes 1993 Probably not randomised trial. We wrote to the author in March 2006, but have not received any reply byMarch
2008
Nicholls 2002 Study design criteria not met. Descriptive case-study.
Pedrazzani 1985 Study design criteria not met. Not a controlled study with an intervention
Pedrazzani 1995 Study design criteria not met. Descriptive study.
Premkumar 1990 Study design criteria not met. Controlled before and after study where people with leprosy act as their own
control
Ramanujam 1953 Study design criteria not met. Controlled before and after study
Sarma 1997 Study intervention criteria not met.
Seboka 1996 Quasi-randomisied trial (day by attendance).
Smith 1995 Study design criteria not met. Cohort study.
Stenstrom 1979
Tuck 1971 Study design criteria not met. Case reports.
Wiseman 1990 Study design criteria not met. Before and after study.
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D A T A A N D A N A L Y S E S
Comparison 1. Zinc tape versus magnesium sulphate/glycerin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of ulcers healed after
one month
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 2. Zinc tape versus povidone iodine (10%)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean reduction of ulcer area at
six weeks
1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 3. Topical ketanserin (2%) versus clioquinol cream (3%) or zinc paste
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Healing of ulcer after three
months
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 4. Topical phenytoin versus saline dressing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean percentage reduction of
ulcer size at four weeks
2 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
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Comparison 5. Footwear canvas shoe versus footwear PVC boot
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of persons being ulcer
free at one year
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Number of persons having ulcers
not healed at one year
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 6. Padded moulded double-rocker plaster shoe versus padded below-knee plaster
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Ulcers fully healed 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Ulcers nearly healed 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Ulcers not healed 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Zinc tape versus magnesium sulphate/glycerin, Outcome 1 Number of ulcers
healed after one month.
Review: Interventions for skin changes caused by nerve damage in leprosy
Comparison: 1 Zinc tape versus magnesium sulphate/glycerin
Outcome: 1 Number of ulcers healed after one month
Study or subgroup Zinc tape
Magnesium
sulph/glyc Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Walton 1986 4/14 2/14 2.00 [ 0.43, 9.21 ]
0.02 0.1 1 10 50
Favours Magnes su/gl Favours zinc tape
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Analysis 2.1. Comparison 2 Zinc tape versus povidone iodine (10%), Outcome 1 Mean reduction of ulcer
area at six weeks.
Review: Interventions for skin changes caused by nerve damage in leprosy
Comparison: 2 Zinc tape versus povidone iodine (10%)
Outcome: 1 Mean reduction of ulcer area at six weeks
Study or subgroup Zinc tape Povidone iodine
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Overbeek 1991 26 388 (498) 12 260 (250) 0.29 [ -0.40, 0.97 ]
-1 -0.5 0 0.5 1
Favours povidone/iod Favours zinc tape
Analysis 3.1. Comparison 3 Topical ketanserin (2%) versus clioquinol cream (3%) or zinc paste, Outcome 1
Healing of ulcer after three months.
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Comparison: 3 Topical ketanserin (2%) versus clioquinol cream (3%) or zinc paste
Outcome: 1 Healing of ulcer after three months
Study or subgroup Ketanserin (2%) clioquinol or zinc Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Salazar 2001 12/33 2/33 6.00 [ 1.45, 24.75 ]
0.05 0.2 1 5 20
Favours clioquinol/z Favours ketanserin
27Interventions for skin changes caused by nerve damage in leprosy (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.1. Comparison 4 Topical phenytoin versus saline dressing, Outcome 1 Mean percentage
reduction of ulcer size at four weeks.
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Comparison: 4 Topical phenytoin versus saline dressing
Outcome: 1 Mean percentage reduction of ulcer size at four weeks
Study or subgroup Phenytoin Saline dressing
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bansal 1993 50 55.5 (21.6) 50 72.1 (19.9) -0.79 [ -1.20, -0.39 ]
Bhatia 2004 15 49.1 (18.2) 15 88.4 (14.2) -2.34 [ -3.30, -1.39 ]
-4 -2 0 2 4
Favours phenytoin Favours saline
Analysis 5.1. Comparison 5 Footwear canvas shoe versus footwear PVC boot, Outcome 1 Number of
persons being ulcer free at one year.
Review: Interventions for skin changes caused by nerve damage in leprosy
Comparison: 5 Footwear canvas shoe versus footwear PVC boot
Outcome: 1 Number of persons being ulcer free at one year
Study or subgroup Canvas shoes PVC boots Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Seboka 1998 20/25 9/13 1.16 [ 0.77, 1.74 ]
0.5 0.7 1 1.5 2
Favours PVC boots Favours canvas shoes
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Analysis 5.2. Comparison 5 Footwear canvas shoe versus footwear PVC boot, Outcome 2 Number of
persons having ulcers not healed at one year.
Review: Interventions for skin changes caused by nerve damage in leprosy
Comparison: 5 Footwear canvas shoe versus footwear PVC boot
Outcome: 2 Number of persons having ulcers not healed at one year
Study or subgroup Canvas shoes PVC boots Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Seboka 1998 4/25 4/13 0.52 [ 0.15, 1.75 ]
0.2 0.5 1 2 5
Favours Canvas Favours PVC
Analysis 6.1. Comparison 6 Padded moulded double-rocker plaster shoe versus padded below-knee plaster,
Outcome 1 Ulcers fully healed.
Review: Interventions for skin changes caused by nerve damage in leprosy
Comparison: 6 Padded moulded double-rocker plaster shoe versus padded below-knee plaster
Outcome: 1 Ulcers fully healed
Study or subgroup Below-knee plaster Plaster shoe Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Pring 1982 18/24 18/31 1.29 [ 0.89, 1.88 ]
0.5 0.7 1 1.5 2
Favours plaster shoe Favours BK plaster
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Analysis 6.2. Comparison 6 Padded moulded double-rocker plaster shoe versus padded below-knee plaster,
Outcome 2 Ulcers nearly healed.
Review: Interventions for skin changes caused by nerve damage in leprosy
Comparison: 6 Padded moulded double-rocker plaster shoe versus padded below-knee plaster
Outcome: 2 Ulcers nearly healed
Study or subgroup Plaster shoe Below-knee plaster Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Pring 1982 8/31 3/24 2.06 [ 0.61, 6.96 ]
0.1 0.2 0.5 1 2 5 10
Favours BK p Favours plaster shoe
Analysis 6.3. Comparison 6 Padded moulded double-rocker plaster shoe versus padded below-knee plaster,
Outcome 3 Ulcers not healed.
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Comparison: 6 Padded moulded double-rocker plaster shoe versus padded below-knee plaster
Outcome: 3 Ulcers not healed
Study or subgroup Below knee plaster Plaster shoes Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Pring 1982 3/24 5/31 0.78 [ 0.21, 2.93 ]
0.2 0.5 1 2 5
Favours BK plaster Favours plaster shoe
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A D D I T I O N A L T A B L E S
Table 1. Quality components
Study Alloca-
tion con-
cealment
Masking
outcome
asse
Loss to
follow up
Similar
baseline
Re-
liable out-
come mea
Interven-
tion
describ
Appropri-
ate analy-
sis
Overall
quality
Method of
random.
Bansal
1993
Inade-
quate
Adequate Adequate Adequate Adequate Adequate Inade-
quate
Moderate Alternately
Bhatia
2004
Unclear Adequate Adequate Adequate Adequate Adequate Unclear Moderate Table
Overbeek
1991
Inade-
quate
Unclear Inade-
quate
Inade-
quate
Unclear Adequate Unclear Low Alternately
Pring 1982 Unclear Unclear Adequate Inade-
quate
Inade-
quate
Unclear Inade-
quate
Low Randomly
divided
Salazar
2001
Unclear Unclear Adequate Adequate Adequate Adequate Adequate Moderate Randomly
allocated
Seboka
1998
Unclear Unclear Adequate Inade-
quate
Unclear Adequate Inade-
quate
Low Randomly
assigned
Söderberg
1982
Inade-
quate
Unclear Adequate Unclear Unclear Adequate Inade-
quate
Low Alternately
Walton
1986
Unclear Unclear Inade-
quate
Unclear Adequate Unclear Unclear Low Consec-
utive cases
randomly
allocated
A P P E N D I C E S
Appendix 1. MEDLINE (OVID ) Search Strategy
1. RANDOMIZED CONTROLLED TRIAL.pt.
2. CONTROLLED CLINICAL TRIAL.pt.
3. RANDOMIZED CONTROLLED TRIALS.sh.
4. RANDOM ALLOCATION.mp.
5. DOUBLE BLIND METHOD.sh.
6. SINGLE-BLIND METHOD.sh.
7. or/1-6
8. animal/ not human/
9. 7 not 8
10. CLINICAL TRIAL.pt.
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11. CLINICAL TRIALS.mp
12. (clin$ adj25 trial$).ti,ab.
13. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
14. PLACEBOS.sh.
15. placebo$.ti,ab.
16. random$.ti,ab.
17. RESEARCH DESIGN.sh.
18. or/10-17
19. 18 not 8
20. 19 not 9
21. COMPARATIVE STUDY.sh.
22. EVALUATION STUDIES.mp
23. FOLLOW UP STUDIES.sh.
24. PROSPECTIVE STUDIES.sh.
25. (control$ or prospectiv$ or volunteer$).ti,ab.
26. or/21-25
27. 26 not 8
28. 27 not (9 or 20)
29. 9 or 20 or 28
30. leprosy.mp. or exp Leprosy/
31. hansens disease.mp.
32. 30 or 31
33. 29 and 32
Appendix 2. EMBASE (OVID) Search Strategy
1. random$.mp.
2. factorial$.mp.
3. crossover$.mp.
4. placebo$.mp. or PLACEBO/
5. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer name]
6. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer name]
7. assign$.mp.
8. volunteer$.mp. or VOLUNTEER/
9. Crossover Procedure/
10. Double Blind Procedure/
11. Randomized Controlled Trial/
12. Single Blind Procedure/
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. leprosy.mp. or exp LEPROSY/
15. hansen’s disease.mp.
16. 14 or 15
17. 13 and 16
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Appendix 3. CINAHL Search Strategy
1. exp Leprosy/
2. leprosy.tw.
3. hansen’s disease.tw.
4. 1 or 2 or 3
5. exp Clinical trials/
6. clinical trial.pt.
7. (clinic$ adj trial$1).tw.
8. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$3 or mask$3)).tw.
9. Randomi?ed control$ trial$.tw.
10. Random assignment/
11. Random$ allocat$.tw.
12. Placebo$.tw.
13. Placebos/
14. Quantitative studies/
15. Allocat$ random$.tw.
16. or/5-15
17. 16 and 4
Appendix 4. LILACS Search Strategy
((Pt randomized controlled trial OR Pt controlled clinical trial ORMh randomized controlled trials ORMh random allocation ORMh
double-blind method OR Mh single-blind method) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Pt clinical
trial OR Ex E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$))
OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR
Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) OR Mh placebos OR Tw placebo$ OR (Tw random$ OR Tw randon$
OR Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR Mh research design) AND NOT (Ct animal AND NOT (Ct
human and Ct animal)) OR (Ct comparative study OR Ex E05.337$ OR Mh follow-up studies OR Mh prospective studies OR Tw
control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animal AND NOT (Ct human and Ct animal)))
[Palavras]and(leprosy or lepra or hansen) [Palavras]and(nerve or nerves or nervio or nervioso) [Palavras]
WH A T ’ S N E W
Last assessed as up-to-date: 19 March 2008.
Date Event Description
8 June 2016 Amended Edited the published note about the updating of the review.
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H I S T O R Y
Protocol first published: Issue 3, 2004
Review first published: Issue 3, 2008
Date Event Description
17 February 2015 Amended This review is going to be updated. We have written a published note to say that because the
inclusion criteria has changed considerably, a new protocol and then a new review will be written
12 August 2013 Amended Author information (affiliation) updated.
27 March 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
Link with editorial base and coordinate contributions from co-reviewers (LMR)
Draft protocol (LMR with contributions from all)
Run search ( LF)
Identify relevant titles and abstracts from searches i.e. broad screen (LMR, LF)
Obtain copies of trials (LMR, LF)
Select which trials to include (LMR, LF with AB as arbitrator when necessary)
Extract data from trials (LMR, LF)
Enter data into RevMan (LMR)
Carry out analysis (LF,LMR)
Interpret analysis (LF,LMR,)
Draft final review (LMR, LF with contribution from all)
Update review (LMR, LF,AB)
D E C L A R A T I O N S O F I N T E R E S T
None known
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S O U R C E S O F S U P P O R T
Internal sources
• Norwegian Knowledge Centre for the Health Services, Norway.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We made some changes to the Background to update it.
In Methods, in the section ’Criteria for considering studies for this review’ under ’Types of studies’ we included trials that used an
alternating allocation.
Under ’Types of outcome measures’ we added tertiary outcomes for ’Participants with no skin/limb damage at entry’. We explained
our reasons for doing this in the section ’Data collection and analysis’ under ’Selection of studies’.
In the same section under ’Measures of treatment effect’ we changed the effect estimate from Odds Ratio stated in the protocol to
Relative Risk. This was because ulcers are quite common in people with nerve damage caused by leprosy.
Also in Methods, in the section ’Search methods for identification of studies’ under ’Searching other resources’ we were unable to
handsearch the Indian Journal of Leprosy as it was not available, and we did not contact adverse events bodies for information.
N O T E S
This review is being updated by way of a new protocol and then a review, because the inclusion criteria has changed considerably.
The citation for the new protocol is as follows: Reinar LM, Forsetlund L, Brurberg KG, Lehman LF. Interventions for ulceration and
other skin changes caused by nerve damage in leprosy (Protocol). Cochrane Database of Systematic Reviews 2016, Issue 6. Art. No.:
CD012235. DOI: 10.1002/14651858.CD012235.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Bandages; Leg Ulcer [etiology; therapy]; Leprosy [∗complications]; Peripheral Nervous SystemDiseases [∗complications]; Randomized
Controlled Trials as Topic; Skin Ulcer [etiology; ∗therapy]; Wound Healing
MeSH check words
Humans
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